Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Podcasting since 2020 • 1066 episodes
Surfing the MASH Tsunami
Latest Episodes
6,13 - Locating MASH patients, Population Screening for Advanced Disease, Impact of Washington on Americans' Health
00:00:00 - Surf's Up: Season 6 Episode 13 Louise Campbell, Jörn Schattenberg and Roger Green continue their discussion of some major issues from earlier this year, while co-authors Aleksander Krag and Stine Johanset join Roger to discu...
•
Season 6
•
Episode 13
•
1:13:53
S6.12.3 - After the Semaglutide Approval: What Next For MASH Therapy?
Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation centers on the roles that new technologi...
•
Season 6
•
Episode 12
•
21:39
S6.12.2 - After the Semaglutide Approval: Expanding MASH Awareness Will Change Medical Practices
Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on how the US healthcare system ...
•
Season 6
•
Episode 12
•
22:58
S6.12.1 - After the Semaglutide Approval: Impact on Patients and Pharmacotherapy
Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on benefits for patients and w...
•
Season 6
•
Episode 12
•
24:35
6.12 - A Second US Drug Approval! What Semaglutide's Success Portends For MASLD Care in the US
00:00:00 - Surf's Up, Season 6, Episode 12This week's episode is a special three-part roundtable on the implications of the FDA's recent approval of semaglutide. Naim Alkhouri, Manal Abdelmalek, Scott Isaacs and Zobair Younossi join Roger G...
•
Season 6
•
Episode 12
•
1:04:23